+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

From
CAR-T Cell Service Market - Global Forecast 2026-2032 - Product Thumbnail Image

CAR-T Cell Service Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 183 Pages
  • Global
From
From
Ewing Sarcoma Therapeutics Market - Global Forecast 2026-2032 - Product Thumbnail Image

Ewing Sarcoma Therapeutics Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 199 Pages
  • Global
From
From
From
Cellular Immunotherapy Market - Global Forecast 2026-2032 - Product Thumbnail Image

Cellular Immunotherapy Market - Global Forecast 2026-2032

  • Report
  • July 2026
  • 182 Pages
  • Global
From
From
From
From
From
CD Antigen Cancer Therapy Market - Global Forecast 2026-2032 - Product Thumbnail Image

CD Antigen Cancer Therapy Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 195 Pages
  • Global
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more